Mean density of computed tomography for predicting rotational atherectomy during percutaneous coronary intervention.

BACKGROUND: Multi-slice computed tomography (CT) allows noninvasive evaluation of the severity of coronary calcification. However, there has yet to be a definitive parameter based on the cross-sectional CT image for predicting the need for rotational atherectomy (RA). Therefore, we aimed to investigate the mean density of cross-sectional CT images to predict the need for RA during percutaneous coronary intervention (PCI). METHODS: A total of 154 lesions with moderate to severe calcification detected in coronary angiography were identified in 126 patients who underwent coronary CT prior to PCI for stable angina. PCI with RA was performed for 48 lesions, and the remaining 106 were treated without RA. Multi-slice CT was retrospectively evaluated for its ability to predict the use of RA. We chose the most severely calcified cross-sectional image for each lesion. The mean density within the outer vessel contour, calcium arc quadrant of the cross-sectional CT image, calcium length, calcification remodeling index, and per-lesion coronary artery calcium score was studied. RESULTS: Receiver-operator characteristic curve analysis revealed 637 Hounsfield units (HU) (area under the curve â€‹= â€‹0.98, 95% confidence interval: 0.97-1.00, p â€‹< â€‹0.001) as the best mean density cutoff value for predicting RA. Multivariate logistic regression analysis showed that a mean calcium level >637 HU was a strong independent predictor (odds ratio: 32.8, 95% confidence interval: 7.0-153, p â€‹< â€‹0.001) for using RA. CONCLUSIONS: The mean density of the cross-sectional CT image, a simple quantitative parameter, was the strongest predictor of the need for RA during PCI.

Assessing the treatment effect of daratumumab by serial measurements of cardiac biomarkers and imaging parameters in light-chain cardiac amyloidosis.

Daratumumab, an anti-human CD38 monoclonal antibody, has become the standard of care in patients with systemic light-chain (AL) amyloidosis and multiple myeloma (MM). Herein, we report two cases of AL cardiac amyloidosis with MM who were treated with daratumumab, lenalidomide, and dexamethasone (DRd). Serial evaluation of cardiac biomarkers, echocardiography, and cardiac magnetic resonance imaging (CMR) were performed during 12 months of DRd treatment. A complete hematologic response was achieved three months after treatment initiation and sustained during the observation period. Twelve months after DRd treatment, we found improvements in levels (values for case 1 and case 2, respectively) of B-type natriuretic peptide (593.2 → 312.2 pg/mL and 202.4 → 104.3 pg/mL), N-terminal pro-brain natriuretic peptide (4005 → 1800 pg/mL and 2576 → 1170 pg/mL), high-sensitivity cardiac troponin T (0.156 → 0.072 ng/mL and 0.0678 → 0.0467 ng/mL), and global longitudinal strain (-6.8 → -10.4 % and -11.8 → -14.8 %). CMR revealed no noticeable changes in native T1 value or extracellular volume fraction. However, one case showed decreased native T2 value (61 → 55 ms). In conclusion, DRd treatment improved heart failure and cardiac function, relieved myocardial damage, and prevented amyloid deposition progression in the patients with AL cardiac amyloidosis. Cardiac biomarkers and imaging findings may be useful for monitoring the therapeutic effects of daratumumab-containing regimens. Learning objective: Daratumumab-containing regimens led to a rapid complete hematologic response, improvements in heart failure symptoms, cardiac function, and regression of myocardial damage in light-chain cardiac amyloidosis. This treatment prevents additional amyloid deposition and suppresses the direct cardiotoxic effects of amyloidogenic immunoglobulin light-chains. Serial assessments of cardiac biomarkers and imaging findings are useful for evaluating the therapeutic effect of daratumumab-containing regimens.